Research Paper Volume 16, Issue 2 pp 1218—1236
Development and validation of a combined cuproptosis and immunogenic cell death prognostic model for diffuse large B-cell lymphoma
Figure 4. Survival analysis of CRIRLs prognostic signature. (A) Age ≥65 (B) Age <65 (C) Male (D) Female (E) Stage I+II (F) Stage III+IV.